
Product Data Sheet

Product Name: Toremifene

Cat. No.: GC11544

Chemical Properties

Cas. No. 89778-26-7

Chemical Name (E)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine

SMILES CN(CCOC1=CC=C(/C(C2=CC=CC=C2)=C(C3=CC=CC=C3)\CCCl)C=C1)CFormula $C_{26}H_{28}ClNO$ M.Wt 405.96

Solubility DMSO : 62.5 mg/mL (153.96 mM; ultrasonic and warming and heat to 60°C) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Background**

IC50 Value: $1 \pm 0.3 \mu M$. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis and other adverse effects resulting from ADT in men with prostate cancer [1]. *in vitro*: The growth of Ac-1 cells was inhibited by tamoxifen, toremifene and atamestane *in vitro* with IC50 values of $1.8 \pm 1.3 \mu M$, $1 \pm 0.3 \mu M$ and $60.4 \pm 17.2 \mu M$, respectively. The combination of toremifene plus atamestane was found to be better than toremifene or atamestane alone *in vitro* [2]. *in vivo*: The effect of this combination was then studied *in vivo* using Ac-1 xenografts grown in ovariectomized female SCID mice. The mice were injected with toremifene (1000 $\mu g/day$), atamestane (1000 $\mu g/day$), tamoxifen (100 $\mu g/day$), or the combination of toremifene plus atamestane. In this study, our results indicate that the combination of toremifene plus atamestane was as effective as toremifene or tamoxifen alone but may not provide any additional benefit over toremifene alone or tamoxifen alone [2]. Clinical trial: Prostate cancer diagnosis among men with isolated high-grade intraepithelial

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene[3].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA